Chris Kaufmann

Chris Kaufmann possesses extensive experience in the biotechnology and healthcare sectors, with a notable career trajectory that includes roles at prestigious companies such as The Boston Consulting Group, Novartis, GSK, and AstraZeneca. As co-founder and president of a nucleic acid-based vaccine company, Chris led efforts in developing COVID vaccines and engaged with regulatory bodies. Previous positions span from managing global operations in Australia and New Zealand for Novartis Vaccines to overseeing commercial evaluations and development at AstraZeneca, with a focus on vaccines and immune therapies. Chris holds a PhD in Molecular Immunology and dual master's degrees in Biochemistry and an MBA in Finance and Healthcare Management, all while contributing to pandemic responses and driving significant growth in vaccine portfolios.